A researcher in a lab using AI to analyze Reddit posts on GLP-1 drug side effects, highlighting symptoms like menstrual changes.
A researcher in a lab using AI to analyze Reddit posts on GLP-1 drug side effects, highlighting symptoms like menstrual changes.
Immagine generata dall'IA

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Immagine generata dall'IA
Verificato

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

A study from the University of Pennsylvania School of Engineering and Applied Science, published in Nature Health in 2026, used large language models to analyze more than 400,000 Reddit posts written by nearly 70,000 users over a period of more than five years.

The researchers reported that many users described side effects commonly associated with GLP-1 drugs, particularly gastrointestinal problems. About 44% of users in the sample mentioned at least one side effect.

The analysis also flagged symptoms that the researchers said may warrant closer scrutiny, while emphasizing that the study does not establish that the medications caused the complaints described online. Nearly 4% of users who reported side effects also described reproductive symptoms, including irregular menstrual cycles, intermenstrual bleeding and heavy bleeding. Users also discussed temperature-related issues such as chills, feeling cold and hot flashes, and fatigue emerged as a frequently mentioned complaint.

The authors suggested that AI-assisted monitoring of large volumes of social media discussion could complement traditional pharmacovigilance by surfacing patient concerns more quickly, while noting that Reddit users are not representative of the broader population and that online reports can be incomplete or biased.

Articoli correlati

Illustration of high-risk patients benefiting from GLP-1 drugs like Ozempic with reduced heart risks
Immagine generata dall'IA

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Riportato dall'IA Immagine generata dall'IA Verificato

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Riportato dall'IA

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Young Indians are turning to diabetes drugs Ozempic and Mounjaro for rapid weight loss before weddings and job interviews, as experts warn of cosmetic misuse, grey market dangers, and rising lookism. These GLP-1 drugs are meant for obesity and diabetes, not vanity purposes, doctors emphasize.

Riportato dall'IA

A minimally invasive procedure called duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing drugs like Ozempic and tirzepatide. Early results from the REMAIN-1 clinical trial show treated participants regained far less weight than those in a control group after six months off medication. The findings are set for presentation at Digestive Disease Week 2026.

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta